A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic parkinson’s disease

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic parkinson’s disease

Optogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingOptogenetic Gene Therapy for Treatment of Retinitis Pigmentosa

Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingTRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

Phase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingPhase 1b Study of TN-401 in Adults with PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingSelective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingAutologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease

• Post author:
• Post published:January 20, 2026
• Post category:

Continue ReadingA Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease